dop: Framework of marketing practices: DoP panel to meet drug pressure groups

The Department of Pharmaceuticals (DoP) will begin discussions with pharmaceutical lobby groups as it begins to review the regulatory framework on marketing practices in the sector. A high-level committee formed under the leadership of VK Paul de Niti Aayog will meet with representatives of pharmaceutical lobby groups this week to consider the matter.

“During the meeting as part of the stakeholder consultations, the committee wanted to hear the views of the Organization of Pharmaceutical Producers of India (OPPI), the Indian Pharmaceutical Alliance (IPA), the ‘Indian Drug Manufacturers Association (IDMA)’, a published notice reads. by the DoP on the meeting, which will be held on 4 November.

Health Minister Mansukh Mandaviya previously formed the committee after reports that companies were spending exorbitantly on drug promotion.

As reported by ET earlier, the committee is considering legal action if companies are found to be involved in unethical marketing practices. “The committee has looked at existing practice and what is needed to ensure the rules are adhered to,” one person with the knowledge said.

The five-member committee is chaired by Paul, NITI Aayog member, health; it includes S Aparna, Secretary of Pharmaceuticals Department, Health Secretary Rajesh Bhushan and Central Board of Direct Tax (CBDT) Chairman Nitin Gupta as members. N Yuvaraj, Deputy Secretary, Policy, DoP, is Member Secretary.

Advertising and promotion by pharmaceutical companies is currently covered by the Uniform Code of Pharmaceutical Marketing Practice (UCPMP), Indian Medical Council Regulations 2002 and the Central Board of Direct Taxation.

Comments are closed.